Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials.

Abstract

OBJECTIVES:

There are very limited data in the oncology literature regarding the survival of women with both platinum and taxane-refractory ovarian cancer.

METHODS:

To examine this issue, we retrospectively reviewed the survival of patients treated on one (or more) of four previously reported nonrandomized single-agent phase 2 trials (topotecan, liposomal doxorubicin, gemcitabine, docetaxel), involving women with well-characterized platinum/taxane-resistant ovarian, fallopian tube, and primary peritoneal cancers. Following their most recent treatment with both classes of agents, patients must have either not responded to therapy or experienced a treatment-free interval of <3 months before documented disease progression.

RESULTS:

The median survival of the 111 patients (median age 61) included in this analysis was 6 months (range 1-37 months). Whereas 36 patients (32%) survived for <4 months, 30 patients (27%) lived for > or =12 months following documentation of resistance to both platinum and taxane therapy.

CONCLUSION:

With currently available antineoplastic drug therapy of platinum/taxane-resistant ovarian cancer, overall survival is relatively short, but a substantial minority of patients can be anticipated to live for periods in excess of 1 year. It remains uncertain whether such unexpectedly prolonged survival results from a biological response to chemotherapy or simply reflects the natural history of disease in a subset of patients with this malignancy.

• Authors: Maurie Markman, Kenneth Webster, Kristine Zanotti, Gertrude Peterson, Barbara Kulp, Jerome Belinson
• Journal: Gynecologic oncology (Gynecol Oncol) Vol. 93 Issue 3 Pg. 699-701 (Jun 2004) ISSN: 0090-8258 [Print] United States
• PMID: 15196867 (Publication Type: Journal Article)

Chemical References

• Bridged-Ring Compounds
• Organoplatinum Compounds
• Taxoids
• Deoxycytidine
• Docetaxel
• taxane
• Topotecan
• Doxorubicin
• Gemcitabine

Topics

• Adult
• Aged
• Aged, 80 and over
• Bridged-Ring Compounds (therapeutic use)
• Clinical Trials, Phase II as Topic
• Deoxycytidine (analogs & derivatives, therapeutic use)
• Docetaxel
• Doxorubicin (therapeutic use)
• Drug Resistance, Multiple
• Drug Resistance, Neoplasm
• Fallopian Tube Neoplasms (drug therapy)
• Female
• Humans
• Middle Aged
• Organoplatinum Compounds (therapeutic use)
• Ovarian Neoplasms (drug therapy)
• Peritoneal Neoplasms (drug therapy)
• Retrospective Studies
• Survival Rate
• Taxoids (therapeutic use)
• Topotecan (therapeutic use)
• Gemcitabine